New Myriad Genetics Survey Uncovers Women Fear Screenings-But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced ...
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Astera Labs ( NASDAQ:ALAB ) , Arista Networks ( NYSE:ANET )
U.S. stocks were mostly higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Shopify Inc. SHOP rose sharply during Wednesday's session after the company reported better-than-expected quarterly sales.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Astera Labs ( NASDAQ:ALAB ) , Digital Turbine ( NASDAQ:APPS )
Shares of Astera Labs, Inc. ALAB rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter guidance above estimates. The company reported a 20% quarter-over-quarter increase in revenue, reaching a record $191.9 ...
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - Myriad Genetics ( NASDAQ:MYGN )
Myriad Genetics Inc. MYGN shares rallied 35.7%, to $5.25 in after-hours trading on Tuesday following second-quarter results that exceeded analyst expectations and raised full-year revenue guidance.
Myriad Genetics ( MYGN ) Q2 Revenue Up 6%
Myriad Genetics ( NASDAQ:MYGN ) , a molecular diagnostics and precision medicine company known for genetic testing in oncology, women's health, and mental health, released its Q2 2025 earnings on August 5, 2025. The most important news was that revenue ( GAAP ) reached $213.1 million, beating the ...
Myriad Genetics ( MYGN ) Q2 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. ( MYGN ) Announced by Holzer & Holzer, LLC - Myriad Genetics ( NASDAQ:MYGN )
ATLANTA, June 25, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. ( "Myriad Genetics" or the "Company" ) MYGN complied with federal securities laws.
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.
Myriad ( MYGN ) Up 23.9% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing ...
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Pennant Park Investment ( NYSE:PNNT ) , Myriad Genetics ( NASDAQ:MYGN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday - Avino Silver & Gold Mines ( AMEX:ASM ) , BGC Group ( NASDAQ:BGC )
U.S. stocks were lower, with the Nasdaq Composite falling around 50 points on Monday. Shares of CI&T Inc. CINT rose sharply during Monday's session. JP Morgan analyst Puneet Jain upgraded CI&T from Neutral to Overweight and announced a $7 price target. CI&T shares jumped 8.2% to $6.60 on Monday.
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference Correction: Time of BofA Conference ...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, May 14, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc. MYGN, a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences:
Down -49.47% in 4 Weeks, Here's Why Myriad ( MYGN ) Looks Ripe for a Turnaround
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, May 07, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc. MYGN, a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast ...
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk ...
Crude Oil Falls 1%; Uber Sales Miss Estimates - CuriosityStream ( NASDAQ:CURI ) , Asset Entities ( NASDAQ:ASST )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Wednesday. The Dow traded up 0.64% to 41,090.68 while the NASDAQ fell 0.20% to 17,655.00. The S&P 500 also rose, gaining, 0.20% to 5,618.00. Consumer discretionary shares rose by 1.2% on Wednesday.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Myriad Genetics ( MYGN ) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Eurobio Scientific: 2024 annual results
2024 ANNUAL RESULTS ...
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, April 25, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc.
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of ...
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
Myriad Genetics Announces Inducement Awards - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, April 08, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc.
Myriad Genetics Announces Inducement Awards
SALT LAKE CITY, April 08, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc. ( NASDAQ: MYGN ) , a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, ...
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Myriad Genetics announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - American Axle & Mfg Hldgs ( NYSE:AXL ) , Alumis ( NASDAQ:ALMS )
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday. Shares of Excelerate Energy, Inc. EE fell sharply in today's pre-market trading. Excelerate Energy announced the pricing of upsized public offering of class A common stock.
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies ( NASDAQ:BIAF ) , Cambium Networks ( NASDAQ:CMBM )
Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Klein and Tommy Hilfiger parent company PVH reported quarterly earnings of $3.27 per share, which beat the analyst consensus estimate of ...
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies ( NASDAQ:BIAF ) , Cambium Networks ( NASDAQ:CMBM )
Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Klein and Tommy Hilfiger parent company PVH reported quarterly earnings of $3.27 per share, which beat the analyst consensus estimate of ...
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Myriad ( MYGN ) Down 17.1% Since Last Earnings Report: Can It Rebound?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Myriad Genetics ( NASDAQ:MYGN )
Piper Sandler upgrades Myriad Genetics to Overweight, raising the price target to $12.50 from $11.50. Myriad Genetics plans to launch a new AI-integrated prostate test later this year or early next year. Find out which stock just plummeted to the bottom of the new Benzinga Rankings.
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Crocs ( NASDAQ:CROX ) , Eaton Corp ( NYSE:ETN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Dave Weiner upgraded the rating for Myriad Genetics, Inc.
Breast Cancer Diagnostics Market Set for 6.9% CAGR Growth, projected to Hit USD 12.45 Billion by 2035
Rockville, MD, March 11, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global breast cancer diagnostics market is estimated to reach a valuation of USD 6,389 million in 2025 and is expected to grow at a CAGR of 6.9% during the ...
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Myriad Genetics announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment.
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO - Myriad Genetics ( NASDAQ:MYGN )
Myriad Genetics earned $4 million from GeneSight testing via UnitedHealthcare in 2024. Myriad reaffirms 2025 EPS guidance of $0.07-$0.11 vs. consensus of $0.06. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading ...
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Myriad Genetics ( MYGN ) Meets Q4 Earnings Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.
Myriad Genetics Included in Forbes America's Best Employers 2025 List
Myriad Genetics has been named on the Forbes list of America's Best Employers 2025.
MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
Pancreatic Cancer Treatment Market to Surge to USD 10.2 Billion by 2034, Driven by Advancements in Immunotherapies and Early Diagnostics - Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. - , Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- The Pancreatic Cancer Treatment Market is set for remarkable growth, projected to reach USD 10.2 billion by 2034, driven by advancements in immunotherapies, targeted therapies, and ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc. MYGN, a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing.
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease ( MRD ) Assay - Myriad Genetics ( NASDAQ:MYGN )
SALT LAKE CITY, Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Myriad Genetics, Inc. MYGN, a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad's ability to bring its ...
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease ( MRD ) Assay
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.
